Trust Co. of Virginia VA Has $14.37 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Trust Co. of Virginia VA increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 103,159 shares of the company’s stock after acquiring an additional 797 shares during the quarter. Johnson & Johnson comprises about 1.9% of Trust Co. of Virginia VA’s investment portfolio, making the stock its 15th largest holding. Trust Co. of Virginia VA’s holdings in Johnson & Johnson were worth $14,368,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Meeder Asset Management Inc. increased its holdings in Johnson & Johnson by 11.1% in the 2nd quarter. Meeder Asset Management Inc. now owns 109,690 shares of the company’s stock valued at $15,277,000 after buying an additional 10,927 shares during the period. Arlington Financial Advisors LLC boosted its stake in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Arlington Financial Advisors LLC now owns 25,597 shares of the company’s stock valued at $3,565,000 after purchasing an additional 405 shares in the last quarter. FLC Capital Advisors boosted its stake in shares of Johnson & Johnson by 11.9% in the 2nd quarter. FLC Capital Advisors now owns 9,065 shares of the company’s stock valued at $1,278,000 after purchasing an additional 967 shares in the last quarter. Freestone Capital Holdings LLC boosted its stake in shares of Johnson & Johnson by 118.8% in the 2nd quarter. Freestone Capital Holdings LLC now owns 67,037 shares of the company’s stock valued at $9,337,000 after purchasing an additional 36,393 shares in the last quarter. Finally, Buckingham Asset Management LLC boosted its stake in shares of Johnson & Johnson by 11.2% in the 2nd quarter. Buckingham Asset Management LLC now owns 50,745 shares of the company’s stock valued at $7,068,000 after purchasing an additional 5,095 shares in the last quarter. 67.23% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently weighed in on the stock. Bank of America restated a “hold” rating and issued a $150.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Barclays initiated coverage on shares of Johnson & Johnson in a research note on Friday, June 21st. They issued a “hold” rating and a $140.00 price target on the stock. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday. Morgan Stanley reiterated an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday. Finally, Raymond James cut their target price on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $150.60.

In other news, Director Marillyn A. Hewson purchased 3,000 shares of the company’s stock in a transaction dated Tuesday, June 11th. The shares were purchased at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the transaction, the director now owns 3,000 shares of the company’s stock, valued at $419,040. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.23% of the stock is currently owned by insiders.

NYSE:JNJ traded down $1.02 during mid-day trading on Wednesday, hitting $128.62. 30,426 shares of the company’s stock were exchanged, compared to its average volume of 7,262,639. The company has a 50 day simple moving average of $131.66 and a 200-day simple moving average of $136.44. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The firm has a market capitalization of $337.10 billion, a P/E ratio of 15.72, a PEG ratio of 2.16 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same period last year, the company earned $2.10 EPS. The firm’s revenue was down 1.3% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a $0.95 dividend. The ex-dividend date is Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.95%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.45%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Balanced Fund

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Intuitive Surgical, Inc.  Shares Acquired by Wedbush Securities Inc.
Intuitive Surgical, Inc. Shares Acquired by Wedbush Securities Inc.
Wedbush Securities Inc. Sells 379 Shares of Facebook, Inc.
Wedbush Securities Inc. Sells 379 Shares of Facebook, Inc.
Strategic Family Wealth Counselors L.L.C. Raises Stock Holdings in Vanguard Small-Cap ETF
Strategic Family Wealth Counselors L.L.C. Raises Stock Holdings in Vanguard Small-Cap ETF
Strategic Family Wealth Counselors L.L.C. Raises Stake in Vanguard High Dividend Yield ETF
Strategic Family Wealth Counselors L.L.C. Raises Stake in Vanguard High Dividend Yield ETF
Palisades Hudson Asset Management L.P. Makes New $212,000 Investment in Merck & Co., Inc.
Palisades Hudson Asset Management L.P. Makes New $212,000 Investment in Merck & Co., Inc.
SPDR S&P Global Natural Resources ETF  Stock Holdings Decreased by Palisades Hudson Asset Management L.P.
SPDR S&P Global Natural Resources ETF Stock Holdings Decreased by Palisades Hudson Asset Management L.P.


© 2006-2019 Ticker Report